Non-HDL-C: new tool uses it to assess long-term CVD risk

  • Brunner FJ & al.
  • Lancet
  • 3 Dec 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Non-high-density lipoprotein cholesterol (HDL-C) is linked to long-term cardiovascular disease (CVD) risk, according to the authors of this multinational study.

Why this matters

  • These authors offer a “simple” tool that uses non-HDL-C for assessing risk and evaluates possible benefits of starting lipid-reducing therapy.

Key results

  • With increasing serum non-HDL-C, 30-year CVD rates increased:
    • 7.7% with
    • 12.8% with
  • Steepest risk increases seen in those under age 45 years at baseline.
  • They found that reducing non-HDL-C by 50% decreased CVD event risk by age 75 years, with increasing benefit with earlier reductions.

Study design

  • Data from the Multinational Cardiovascular Risk Consortium, 19 countries in Europe, Australia, and North America.
  • 398,846 participants from 38 cohorts; of these, 199,415 were in the derivation cohort and 199,431 were used for validation.
  • Funding: EU Framework Programme, others.

Limitations

  • Only baseline lipid values used.
  • Most participants were of European ancestry.